Search

Search Results

1. Maribavir: First Approval

   Maribavir (LIVTENCITY ^TM ), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of...

   Connie Kang in Drugs

   Article 11 February 2022
   

2. Oteseconazole: First Approval

   Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections....

   Sheridan M. Hoy in Drugs

   Article 17 June 2022
   

3. Vutrisiran: First Approval

   Vutrisiran (AMVUTTRA™) is a subcutaneously administered transthyretin-directed small interfering ribonucleic acid (siRNA) therapeutic (also called...

   Susan J. Keam in Drugs

   Article 23 August 2022
   

4. Healthcare costs of patients with chronic obstructive pulmonary disease in Denmark – specialist care versus GP care only

   Background

   Many patients with chronic obstructive pulmonary disease (COPD) are treated in general practice only and have never received specialist...

   Jesper Lykkegaard, Jesper Bo Nielsen, ... Jens Søndergaard in BMC Health Services Research

   Article Open access 28 March 2022
   

5. Intraoperatives Floppy-Iris-Syndrom – Gibt es Neuigkeiten zur systemischen Medikation?

   Background

   Intraoperative floppy iris syndrome (IFIS) is known to be a potential cause of serious complications during cataract surgery. Multiple...

   Birgit Weingessel, Jolanda Steininger, ... Veronika Vécsei-Marlovits in Spektrum der Augenheilkunde

   Article 01 April 2022
   

6. Why is There Discordance between the Reimbursement of High-Cost ‘Life-Extending’ Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia

   New health technologies often yield health benefits, but often at a high cost. In Australia, the processes for public reimbursement of high-cost...

   Sopany Saing, Naomi van der Linden, ... Stephen Goodall in Applied Health Economics and Health Policy

   Article 25 March 2019

7. Daridorexant: First Approval

   Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX ₁ and OX ₂ ) receptor antagonist...

   Anthony Markham in Drugs

   Article Open access 17 March 2022
   

8. Ganaxolone: First Approval

   Ganaxolone (ZTALMY ^® ; Marinus Pharmaceuticals) is a synthetic neuroactive steroid that acts as a positive allosteric modulator of the...

   Yvette N. Lamb in Drugs

   Article 21 May 2022
   

9. Pharmaceuticals are back in the Game for OSA Treatment

   Nikolaus Netzer, Petra G. Netzer, ... Arn H. Eliasson in Sleep and Breathing

   Article 05 July 2019

10. Okuläre Nebenwirkungen von Dupilumab – Übersichtsarbeit und Therapieempfehlung der „Kommission für Trockenes Auge und Oberflächenerkrankungen“ der Österreichischen Ophthalmologischen Gesellschaft (ÖOG)

    Dupilumab (Dupixent®, Sanofi and Regeneron Pharmaceuticals) is a human monoclonal antibody against the interleukin (IL)-4 receptor alpha subunit of...

    Nora Woltsche, Julia Aschauer, ... Jutta Horwath-Winter in Spektrum der Augenheilkunde

    Article Open access 12 September 2023
    

11. PrAna: an R package to calculate and visualize England NHS primary care prescribing data

    Background

    The objective of this work to calculate prescribed quantity of an active pharmaceutical ingredient (API) in prescription medications for...

    Kishore Kumar Jagadeesan, James Grant, ... Barbara Kasprzyk-Hordern in BMC Medical Informatics and Decision Making

    Article Open access 06 January 2022
    

12. How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes

    Background

    Although pharmaceutical expenditures have been rising for decades, the question of their drivers remains unclear, and long-term projections...

    Valeska Hofbauer-Milan, Stefan Fetzer, Christian Hagist in PharmacoEconomics

    Article Open access 25 February 2023
    

13. Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

    Purpose of Review

    [ ¹⁷⁷ Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen...

    Daria Arbuznikova, Matthias Eder, ... Ann-Christin Eder in Current Oncology Reports

    Article Open access 20 October 2023
    

14. Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context

    Background

    Patients use medical cannabis for a wide array of illnesses and symptoms, and many substitute cannabis for pharmaceuticals. This...

    Alexis Holman, Daniel J. Kruger, ... Kevin F. Boehnke in Journal of Cannabis Research

    Article Open access 13 June 2022

15. Carboxymethylcellulose excipient allergy: a case report

    Background

    Excipients are widely used in pharmaceuticals, detergents, food, and drink because of their properties of low toxicity and...

    Katherine Townsend, James Laffan, Grant Hayman in Journal of Medical Case Reports

    Article Open access 24 November 2021
    

16. Case of a 6-year-old boy with anaphylaxis induced by erythritol with positive skin prick test and negative basophil activation test

    Erythritol is widely used as an additive in foods and pharmaceuticals. We present the case of a 6-year-old boy who developed an allergy to...

    Satomi Mori, Kazuyuki Kurihara, Chisato Inuo in Allergy, Asthma & Clinical Immunology

    Article Open access 24 March 2022
    

17. Non-targeted analysis (NTA) and suspect screening analysis (SSA): a review of examining the chemical exposome

    Abstract

    Non-targeted analysis (NTA) and suspect screening analysis (SSA) are powerful techniques that rely on high-resolution mass spectrometry...

    Katherine E. Manz, Anna Feerick, ... Joshua A. Young in Journal of Exposure Science & Environmental Epidemiology

    Article Open access 28 June 2023
    

18. Sugemalimab: First Approval

    Sugemalimab (Cejemly ^® in China) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody...

    Sohita Dhillon, Sean Duggan in Drugs

    Article 17 March 2022
    

19. Maralixibat: First Approval

    Maralixibat (Livmarli™) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum...

    Matt Shirley in Drugs

    Article Open access 23 November 2021
    

20. Direct and indirect savings from parallel imports in Sweden

    Background

    The aim was: i) to quantify the direct and indirect savings from parallel imports in Sweden during a period when sellers were forbidden...

    David Granlund in Health Economics Review

    Article Open access 31 August 2022